Show notes
“Once you start measuring a joint or a tissue, you realize that the signal of disease is in the data long before anyone feels a symptom.”
Ilya Burkov is Global Head of Scientific AI & Healthcare at Nebius. Ilya's parents had one rule for every childhood ambition, astronaut, fireman, chef: get a foundation first, then choose. He took it seriously. Sports year round, science projects, Scouts trips, and around ten A levels, because biology, law, electronics, and further maths all seemed worth knowing. Where did the road really start? A hospital, he says, where he volunteered as a teenager, brought tea to long-term patients, and kept noticing that homes had Dysons while wards had old fans.
That question about outdated hospital tech sent him hunting for a field that fused medicine with engineering, right as biomedical engineering degrees first appeared in the UK. He calls the course a Frankenstein of chemical, electronic, and mechanical engineering stitched onto anatomy and patient care. A master's in nanomedicine followed, just as stem cells and drug delivery were breaking through. His dissertation asked whether cartilage damage in osteoarthritis could be reversed, and that question pulled him toward the imaging biomarkers that flag disease long before symptoms.
It ends with a stroke of luck: an interview he took out of curiosity while planning a move to France. Two hours later, the phone rang. Professor Ken Poole, the one interviewer he'd genuinely enjoyed, would be his PhD supervisor at Cambridge.

